Cencora, Inc. (NYSE:COR) Shares Sold by PGGM Investments

PGGM Investments cut its stake in Cencora, Inc. (NYSE:COR) by 23.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,993 shares of the company’s stock after selling 19,167 shares during the period. PGGM Investments’ holdings in Cencora were worth $14,153,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Hickory Asset Management Inc. bought a new stake in shares of Cencora during the fourth quarter valued at approximately $572,000. Sylvest Advisors LLC bought a new stake in Cencora during the 4th quarter valued at $1,105,000. Insight Wealth Strategies LLC boosted its position in Cencora by 124.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock worth $4,549,000 after acquiring an additional 11,232 shares during the period. Cerity Partners LLC grew its stake in shares of Cencora by 10.1% in the third quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after purchasing an additional 3,610 shares in the last quarter. Finally, Vontobel Holding Ltd. increased its holdings in shares of Cencora by 46.9% during the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company’s stock valued at $1,403,000 after purchasing an additional 1,995 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the transaction, the chief executive officer now directly owns 51,070 shares in the company, valued at approximately $13,022,850. The trade was a 8.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,648 shares of company stock worth $3,382,462. Company insiders own 10.80% of the company’s stock.

Cencora Trading Down 2.6 %

Shares of NYSE:COR opened at $253.88 on Thursday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market capitalization of $49.23 billion, a price-to-earnings ratio of 36.11, a PEG ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $263.70. The company has a 50 day moving average price of $246.39 and a 200 day moving average price of $238.81.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.87%. Cencora’s dividend payout ratio is currently 31.29%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on COR. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Mizuho started coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Wells Fargo & Company boosted their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.